Using Clinical Trial Simulators to Analyse the Sources of Variance in Clinical Trials of Novel Therapies for Acute Viral Infections

BACKGROUND: About 90% of drugs fail in clinical development. The question is whether trials fail because of insufficient efficacy of the new treatment, or rather because of poor trial design that is unable to detect the true efficacy. The variance of the measured endpoints is a major, largely undere...

Descripción completa

Detalles Bibliográficos
Autores principales: Vegvari, Carolin, Cauët, Emilie, Hadjichrysanthou, Christoforos, Lawrence, Emma, Weverling, Gerrit-Jan, de Wolf, Frank, Anderson, Roy M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4917234/
https://www.ncbi.nlm.nih.gov/pubmed/27332704
http://dx.doi.org/10.1371/journal.pone.0156622

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4917234/
https://www.ncbi.nlm.nih.gov/pubmed/27332704
http://dx.doi.org/10.1371/journal.pone.0156622

Ejemplares similares